
|Videos|July 22, 2016
Dr. Hristos Kaimakliotis on Predictive Markers in Bladder Cancer
Author(s)Hristos Kaimakliotis, MD
Advertisement
Hristos Kaimakliotis, MD, assistant professor, Indiana University School of Medicine, discusses predictive markers in bladder cancer.
Homologous recombination repair-deficiency (HRD) and cell cycle progression (CCP) have been identified in DNA repair pathways as potential predictors of tumor behaviors, says Kaimakliotis.
After investigating HRD and CCP assays, it was determined that higher CCP and HRD scores were associated with pathological complete responses (pCR) and decreased risk of recurrence.
In a mutation analysis, it was determined that P53 and RB1 mutations were associate with pCRs as well.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
The OncFive: Top Oncology Articles for the Week of 1/25
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5



































